SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Cochlear Limited CHEOY OTC

Other OTC • Healthcare • Medical - Devices • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Cochlear Limited (CHEOY) is a Medical - Devices company in the Healthcare sector, currently trading at $62.80. It has a SharesGrow Score of 87/100, indicating a strong investment profile with 7 out of 7 criteria passed.

Analyst consensus target is CHEOY = $319 (+407.2% upside).

Financials: revenue is $2.3B, +12.8%/yr average growth. Net income is $389M, growing at +10.6%/yr. Net profit margin is 16.6% (healthy). Gross margin is 73.7% (-1.3 pp trend).

Balance sheet: total debt is $236M against $2.0B equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 2.35 (strong liquidity). Debt-to-assets is 8.3%. Total assets: $2.8B.

SharesGrow 7-Criteria breakdown: Value 89/100 (Pass), Growth 80/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 70/100 (Pass), Future 100/100 (Pass), Income 70/100 (Pass).

CHEOY SharesGrow Score Overview

87/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 89/100

Valuation — P/E, PEG, Forward PEG

GROWTH 80/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 70/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CHEOY

CHEOY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $319, implying +408% from the current price $63. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CHEOY: +12.8%/yr revenue is, +10.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CHEOY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CHEOY: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 2.35 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CHEOY: Gross margin is 73.7% (-1.3 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 0 analysts rate CHEOY as buy. Analyst consensus target is $319 (+408% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CHEOY: Net profit margin is 16.6%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range56.07-105.6

Volume7.6K

Avg Volume (30D)45.53K

Market Cap$8.25B

Beta (1Y)0.51

Dividend Yield$1.3114

Share Statistics

EPS (TTM)2.97

Shares Outstanding$130.88M

IPO Date2010-04-05

Employees4,996

CEODiggory William Howitt

Financial Highlights & Ratios

Revenue (TTM)$2.34B

Gross Profit$1.73B

EBITDA$619.9M

Net Income$388.9M

Operating Income$406.1M

Total Cash$275.7M

Total Debt$235.7M

Net Debt$-40M

Total Assets$2.83B

Price / Earnings (P/E)21.1

Price / Sales (P/S)3.52

Analyst Forecast

1Y Price Target$318.50

Target High$332.00

Target Low$305.00

Upside+407.2%

Company Info

CountryAU

ExchangeOther OTC

CurrencyUSD

ISINUS1914592050

Price Chart

CHEOY

Cochlear Limited ↗ · Other OTC

Healthcare • Medical - Devices

56.07 52WK RANGE 105.60

People Also View

Abbott Laboratories

Stryker Corporation

Boston Scientific Corporation

Siemens Healthineers AG

Edwards Lifesciences Corporation

Smith & Nephew plc

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message